Nomination Committee for Elicera Therapeutics appointed
Gothenburg, November 4, 2021 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncological treatments focused on CAR T-cells and oncolytic viruses, announces that representatives of the largest owners have appointed the nomination committee ahead of the Annual General Meeting 2022.On April 26, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners on September 30 2021, were Magnus Essand, Di Yu and Jamal El-Mosleh, who together control 47.1% of the votes, and will be the